Article Sidebar

Submitted
Apr 20, 2021
Published
Apr 20, 2021
Download
PDF
Statistic
Read Counter : 51 Download : 27

Main Article Content

Abstract

Aim: To explore the therapeutic usefulness of the proteolytic enzyme Serratiopeptidase in the treatment of Hyperlipidemia and Atherosclerosis.


Materials & Methods: We observed the anti-atherosclerotic and anti-hyperlipidemic activity of Serratio peptidase in atherogenic diet (AD) and Triton X-100 induced male albino wistar rats (150-200g). Animals were separated randomly into 5 groups with 6 rats in each group. Disease control, test groups and standard groups were administered with Triton X-100 (100mg/kg, i.p.) and fed with that of atherogenic diet for 21 days where as normal control rats were fed with normal diet. Test and standard groups were administered with Serratiopeptidase (10 mg/kg, p.o.low dose) and Fenofibrate (50mg/kg, p.o. high dose) subsequently for 21 days. Studies were undertaken to evaluate the effect of serratiopeptidase on physical and serum biochemical parameters by comparing the treated group with disease and normal control for every 7 days. Statistical analysis was carried out using two way ANOVA followed by Bonferroni’s multiple comparison test.


Results:  Serratiopeptidase had shown a significant (p < 0.05) reduction in the body weights and lipid levels such as LDL, VLDL, TGL, TC, Atherogenic index and shown a significant (p < 0.05) increase in HDL-C. Significant


(p < 0.05) improvement was also observed in atherogenic index. The results were compared with the standard. Histopathology of coronary arteries indicated the significant reduction in the lesion size in test and standard groups when compared with disease control.


Conclusion: Thus, it can be indicated that serratiopeptidase has a significant control in hyperlipidemic and atherosclerotic rats. The study can be further processed clinically as there is a need of a good anti-atherosclerotic & anti-hyperlipidemic drug without or less side effects.

Keywords

Serratiopeptidase Protease Metalloproteinase Hyperlipidemia Atherosclerosis Fibrinolysis Fenofibrate Peroxisome proliferator-activated receptor

Article Details

How to Cite
Gudeppu Mounika, B. Chaitanya, Raju Bairi, & T. Radhika. (2021). Effect of serratiopetidase on Triton X-100 induced hyperlipidemic and atherosclerotic rats. International Journal of Research in Pharmacology & Pharmacotherapeutics, 4(1), 131-139. https://doi.org/10.61096/ijrpp.v4.iss1.2015.131-139
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. [1] S.P Prabha, P.N Ansil, A. Nitha, P.J Wills, M.S Latha. Anti-atherogenic activity of methanolic extract of gardenia gummiferalinn.f. on high fat diet induced atherosclerosis in rats . Int J Pharm Sci. 5(2), 2013, 388-93.
  2. [2] Insull W Jret al. The pathology of atherosclerosis: plaque development and plaque responses to medical treatment. Am J Med. 122, 2009, S3-S14.
  3. [3] K. Hari Kumar et al. A Review on Hyperlipidemic. IJNTPS. 3, 2013, 159-171.
  4. [4] Sagar P et.al. Therapeutic approaches to drug targets in hyperlipidemia. Biomedicine. 2, 2012, 137-146.
  5. [5] Chaudhari SA, Mali AK. Production, characterization & optimization of potent protease (serratiopeptidase) from Serratiamarscens E15.Int. Res J Pharm. App Sci. 3(4), 2013, 95-8.
  6. [6] Jyothi P, Kiran KJ, Radhika M. Antimicrobial studies of selected antibiotics and their combination with enzymes. Int J Pharmacy Pharm Sci. 2 (3), 2010, 43-4.
  7. [7] Misraulia.K.S, Kaskhedikar.P. Ulcerogenic activity of certain non-steroidal anti-inflammatory drugs and enzymes on gastric mucosa of rats. Indian J. Field Vet.6, 2010, 42-4.
  8. [8] R. Garg, Shafiq.A, Garg.A, Walia.R. Prospective Comparative Study of serratiopeptidase and aceclofenacin Upper and Lower Limb Soft Tissue Trauma Cases.IJPPT.1, 2012, 2277 –3436.
  9. [9] Fadi NN, Ahmed HH, Booles HF, Sayed AH.Serrapeptase and nattokinase intervention for relieving Alzheimer’s disease pathophysiology in rat model. Hum ExpToxicol Jul. 32(7), 2013, 721-35.
  10. [10] Ehab MM, Mahdi YM. Serratiopeptidase a Hope in a Rapid and Better Improvement of Inflammatory Acne Vulgaris. Iraqi J Pharm Sci. 21(1), 2012, 78-81.
  11. [11] Mecikoglu M, Saygi B, Yilidrim Y, Karadag-Saygi E, Ramadan SS, Esemenli T. (2006) The effect of proteolytic enzyme serratiopeptidase in the treatment of experimental implant-related infection. J Bone Joint Surg Am. 88(6), 2006, 1208-14.
  12. [12] Gerhard Vogel. (2002). Anti-Atherosclerotic Activity, 2nd edition (p.1676-77). Newyork: Springer-Verlag Berlin Heidelberg.
  13. [13] Sudha S.S, Karthic R, R. Naveen, J.Rengaramanujam. Anti hyperlipidemic activity of Spirulinaplatensis in Triton X-100 induced hyperlipidemic rats. Hygeia.J.D.Med. 3(2), 2011, 32-37.
  14. [14] Chatzizisis YS, et al.Prediction of the localization of high-risk coronary atherosclerotic plaques on the basis of low endothelial shear stress: an intravascular ultrasound and histopathology natural history study. Circulation. 117(8), 2008, 993-1002.
  15. [15] Dhandapani R. Hypolipidemic activity of Ecliptaprostrata (L.) L. leaf extract in atherogenic diet induced hyperlipidemic rats. Indian J Exp Biol. 45(7), 2007, 617-9.
  16. [16] Friedewald, W.T, Levy, R.I, Friedrickson, D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin.Chem. 18, 1972, 499-502.
  17. [17] Davidson M et.al. Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib.Lipid Res.54, 2013, 467-72.
  18. [18] Koley D, Bard AJ. Triton X-100 concentration effects on membrane permeability of a single HeLa cell by scanning electrochemical microscopy (SECM). ProcNatlAcad Sci.107, 2010, 16783-87.
  19. [19] RK Srivastav, Siddiqui HH, Imam MT, Ahsan F. Evaluation of cardioprotective effect of silk cocoon (Abresham) on isoprenaline-induced myocardial infarction in rats. Avicenna J Phytomed.3(3), 2013, 216-23.